BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 24467221)

  • 1. Treatment of de novo acute myeloid leukemia in the United States: a report from the Patterns of Care program.
    Doria-Rose VP; Harlan LC; Stevens J; Little RF
    Leuk Lymphoma; 2014 Nov; 55(11):2549-55. PubMed ID: 24467221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The state of the union on treatment of acute myeloid leukemia.
    Emadi A; Karp JE
    Leuk Lymphoma; 2014 Nov; 55(11):2423-5. PubMed ID: 24576164
    [No Abstract]   [Full Text] [Related]  

  • 3. Prolonged treatment with arsenic trioxide (ATO) and all-trans-retinoic acid (ATRA) for relapsed acute promyelocytic leukemia previously treated with ATRA and chemotherapy.
    Cicconi L; Breccia M; Franceschini L; Latagliata R; Molica M; Divona M; Diverio D; Rizzo M; Ottone T; Iaccarino L; Alfonso V; Foa R; Voso MT; Lo-Coco F
    Ann Hematol; 2018 Oct; 97(10):1797-1802. PubMed ID: 29951912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical characteristics and outcome of childhood acute promyelocitic leukemia (APL) in Saudi Arabia: a multicenter SAPHOS leukemia group study.
    Jastaniah W; Alsultan A; Al Daama S; Ballourah W; Bayoumy M; Al-Anzi F; Al Shareef O; Abrar MB; Al Sudairy R; Al Ghemlas I
    Hematology; 2018 Jul; 23(6):316-323. PubMed ID: 29212418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcome of Adolescents and Young Adults Compared With Pediatric Patients With Acute Myeloid and Promyelocytic Leukemia.
    Nasir SS; Giri S; Nunnery S; Martin MG
    Clin Lymphoma Myeloma Leuk; 2017 Feb; 17(2):126-132.e1. PubMed ID: 27836483
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autologous and allogeneic stem-cell transplantation as salvage treatment of acute promyelocytic leukemia initially treated with all-trans-retinoic acid: a retrospective analysis of the European acute promyelocytic leukemia group.
    de Botton S; Fawaz A; Chevret S; Dombret H; Thomas X; Sanz M; Guerci A; San Miguel J; de la Serna J; Stoppa AM; Reman O; Stamatoulas A; Fey M; Cahn JY; Sotto JJ; Bourhis JH; Parry A; Chomienne C; Degos L; Fenaux P
    J Clin Oncol; 2005 Jan; 23(1):120-6. PubMed ID: 15534358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.
    Hershman D; Neugut AI; Jacobson JS; Wang J; Tsai WY; McBride R; Bennett CL; Grann VR
    J Natl Cancer Inst; 2007 Feb; 99(3):196-205. PubMed ID: 17284714
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is There Still a Role for Low-Dose All-Transretinoic Acid in the Treatment of Acute Promyelocytic Leukemia in the Arsenic Trioxide Era?
    Jaime-Pérez JC; González-Leal XJ; Pinzón-Uresti MA; Gómez-De León A; Cantú-Rodríguez OG; Gutiérrez-Aguirre H; Gómez-Almaguer D
    Clin Lymphoma Myeloma Leuk; 2015 Dec; 15(12):816-9. PubMed ID: 26500134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute megakaryocytic leukemia is associated with worse outcomes than other types of acute myeloid leukemia.
    Giri S; Pathak R; Prouet P; Li B; Martin MG
    Blood; 2014 Dec; 124(25):3833-4. PubMed ID: 25498456
    [No Abstract]   [Full Text] [Related]  

  • 10. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial.
    Burnett AK; Russell NH; Hills RK; Bowen D; Kell J; Knapper S; Morgan YG; Lok J; Grech A; Jones G; Khwaja A; Friis L; McMullin MF; Hunter A; Clark RE; Grimwade D;
    Lancet Oncol; 2015 Oct; 16(13):1295-305. PubMed ID: 26384238
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment and outcomes for chronic myelomonocytic leukemia compared to myelodysplastic syndromes in older adults.
    Zandberg DP; Huang TY; Ke X; Baer MR; Gore SD; Smith SW; Davidoff AJ
    Haematologica; 2013 Apr; 98(4):584-90. PubMed ID: 23144192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved treatment results for childhood acute myeloid leukemia in Taiwan.
    Liang DC; Chan TT; Lin KH; Lin DT; Lu MY; Chen SH; Liu HC; Lin MT; Lee MT; Shu SG; Chang TK; Chen JS; Hsiao CC; Hung IJ; Hsieh YL; Chen RL; Cheng SN; Chang WH; Lee CH; Lin KS
    Leukemia; 2006 Jan; 20(1):136-41. PubMed ID: 16281075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Big data analysis of treatment patterns and outcomes among elderly acute myeloid leukemia patients in the United States.
    Medeiros BC; Satram-Hoang S; Hurst D; Hoang KQ; Momin F; Reyes C
    Ann Hematol; 2015 Jul; 94(7):1127-38. PubMed ID: 25791241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapy-related myeloid leukemia after treatment for epithelial ovarian carcinoma: an epidemiological analysis.
    Vay A; Kumar S; Seward S; Semaan A; Schiffer CA; Munkarah AR; Morris RT
    Gynecol Oncol; 2011 Dec; 123(3):456-60. PubMed ID: 21855120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Feasibility and results of autologous stem cell transplantation in de novo acute myeloid leukemia in patients over 60 years old. Results of the CETLAM AML-99 protocol.
    Oriol A; Ribera JM; Esteve J; Guàrdia R; Brunet S; Bueno J; Pedro C; Llorente A; Tormo M; Besalduch J; Sánchez JM; Batlle M; Vivancos P; Carreras E; Vilà JM; Julià A; Sierra J; Montserrat E; Feliu E;
    Haematologica; 2004 Jul; 89(7):791-800. PubMed ID: 15257930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia Registry.
    Lehmann S; Ravn A; Carlsson L; Antunovic P; Deneberg S; Möllgård L; Derolf AR; Stockelberg D; Tidefelt U; Wahlin A; Wennström L; Höglund M; Juliusson G
    Leukemia; 2011 Jul; 25(7):1128-34. PubMed ID: 21502956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of cytarabine in paediatric acute promyelocytic leukemia treated with the combination of all-trans retinoic acid and arsenic trioxide: a randomized controlled trial.
    Zhang L; Zou Y; Chen Y; Guo Y; Yang W; Chen X; Wang S; Liu X; Ruan M; Zhang J; Liu T; Liu F; Qi B; An W; Ren Y; Chang L; Zhu X
    BMC Cancer; 2018 Apr; 18(1):374. PubMed ID: 29615003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical impact of CD25 expression on outcomes of allogeneic hematopoietic stem cell transplant for cytogenetically intermediate-risk acute myeloid leukemia.
    Ikegawa S; Doki N; Yamamoto K; Shingai N; Takahashi Y; Aoki J; Yoshioka K; Narukawa K; Ishida S; Igarashi A; Oshikawa G; Kobayashi T; Kakihana K; Sakamaki H; Haraguchi K; Okuyama Y; Ohashi K
    Leuk Lymphoma; 2015 Jun; 56(6):1874-7. PubMed ID: 25311493
    [No Abstract]   [Full Text] [Related]  

  • 19. Survival difference between secondary and de novo acute myeloid leukemia by age, antecedent cancer types, and chemotherapy receipt.
    Sedeta E; Jemal A; Nisotel L; Sung H
    Cancer; 2024 Jun; 130(11):1952-1963. PubMed ID: 38244208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Arsenic trioxide therapy for relapsed acute promyelocytic leukemia: a bridge to transplantation.
    Leoni F; Gianfaldoni G; Annunziata M; Fanci R; Ciolli S; Nozzoli C; Ferrara F
    Haematologica; 2002 May; 87(5):485-9. PubMed ID: 12010661
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.